PET Drug Production Laboratory

Mission

To provide PET radiopharmaceuticals for translational imaging research and clinical patient care using the state-of-the-art CGMP- compliant production facility at WIMR.

Rationale

The increasing role of molecular imaging in personalized medicine to diagnose, stage and monitor treatment requires the production of PET radiopharmaceuticals compliant with FDA regulations. PET radiopharmaceuticals produced in this facility are intended for human use either for research under RDRC or INDs or for clinical use under NDAs.